N/A
Completed N=1,484
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
Source: ClinicalTrials.gov NCT05286528 ↗Enrolled (actual)
1,484
Serious AEs
—
Results posted
Oct 2023
Primary outcomePrimary: Overall Survival Rate: All Participants — 77.1 Percentage of participants
Summary
The objectives of this study are to describe patient demographics, clinical and disease characteristics and treatment patterns of Chronic Lymphoid Leukaemia (CML) in Hungary.
The primary endpoint of this study is the overall survival of CML patients treated with tyrosine kinase inhibitors in Hungary. The Overall Survival (OS) of all enrolled patients, OS by sequence pattern and by the number of treatment lines will be analyzed.
Secondary objectives are description of the treatment length in 1st and later lines, incidence and prevalence of CML, the patient demographics (as age, gender, comorbidities), average number of patients' comorbidities, most frequent comorbidities and patient number with comorbidities at baseline and at different treatment lines by investigated Thyrosine Kinase Inhibitor (TKI), distribution of the investigated TKI therapies by treatment lines
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Survival Rate: All Participants |
77.1 | — |
| PRIMARY Overall Survival Rate: Type of First Line TKI |
77.1 | — |
| PRIMARY Overall Survival Rate: Type of Second Line TKI |
71.5 | — |
| PRIMARY Overall Survival Rate: Per Sequence of Treatment |
— | — |
Eligibility Criteria
Inclusion Criteria
- Female and male patients diagnosed with chronic myeloid leukemia
- Patients receiving tyrosine kinase inhibitor therapy under the terms of the current marketing authorization
Exclusion Criteria
- Patients receiving TKI for non-CML diagnoses
Data sourced from ClinicalTrials.gov (NCT05286528). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.